Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
myelodysplastic syndrome (MDS)
Biotech
Orca prepares to make market plunge after phase 3 win
Orca-T offers “good efficacy and low toxicity,” CEO Ivan Dimov said, noting that the combination of features represents the "holy grail" in the space.
Gabrielle Masson
Mar 17, 2025 7:00am
Takeda pays Keros $200M upfront for rival to BMS' Reblozyl
Dec 3, 2024 7:30am
Syros flunks phase 3 blood cancer trial, triggering loan default
Nov 13, 2024 10:00am
Molecular Partners tweaks AML trial over 'suboptimal exposure'
Aug 27, 2024 10:00am
New EHA data show how Gilead's $4.9B bet on CD47 imploded
Jun 14, 2024 2:03pm
Geron secures 12-2 AdComm vote in favor of blood cancer drug
Mar 15, 2024 5:00am
